Page last updated: 2024-08-26

mci 9038 and Retinal Diseases

mci 9038 has been researched along with Retinal Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Honda, Y; Katsuta, H; Kiryu, J; Miyahara, S; Miyamoto, K; Nishijima, K; Nonaka, A; Tsujikawa, A; Yamashiro, K	1

Other Studies

1 other study(ies) available for mci 9038 and Retinal Diseases

Article	Year
Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia. Stroke, 2003, Volume: 34, Issue:8 Topics: Animals; Arginine; Blood Platelets; Cell Adhesion; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Intercellular Adhesion Molecule-1; Ischemia; Leukocytes; Male; P-Selectin; Partial Thromboplastin Time; Pipecolic Acids; Platelet Aggregation Inhibitors; Prothrombin Time; Rats; Rats, Long-Evans; Reperfusion; Retina; Retinal Diseases; Retinal Vessels; RNA, Messenger; Sulfonamides; Thrombin; Treatment Outcome; Vascular Patency	2003

Article

Year

Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia.

Stroke, 2003, Volume: 34, Issue:8

Topics: Animals; Arginine; Blood Platelets; Cell Adhesion; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Intercellular Adhesion Molecule-1; Ischemia; Leukocytes; Male; P-Selectin; Partial Thromboplastin Time; Pipecolic Acids; Platelet Aggregation Inhibitors; Prothrombin Time; Rats; Rats, Long-Evans; Reperfusion; Retina; Retinal Diseases; Retinal Vessels; RNA, Messenger; Sulfonamides; Thrombin; Treatment Outcome; Vascular Patency

2003